ArticleScientific reports2020
Expression of SARS-CoV-2 entry factors in lung epithelial stem cells and its potential implications for COVID-19.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Mucosal immune response in biology, disease prevention and treatment.Signal transduction and targeted therapy · 2025Pooled it
- Stem Cells as a Model of Study of SARS-CoV-2 and COVID-19: A Systematic Review of the Literature.BioMed research international · 2021Pooled it
- SARS-CoV-2 drives upregulation of EpCAM in respiratory epithelial cells with hypercellular profile during severe COVID-19.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Evaluating imputation methods for accurate estimation of cell population fractions in single-cell RNA sequencing.NAR genomics and bioinformatics · 2026Article
- The long reach of influenza and other respiratory viruses: from acute epithelial injury to post-viral lung disease.Clinical microbiology reviews · 2025Review
- Complex Analysis of Single-Cell RNA Sequencing Data.Biochemistry. Biokhimiia · 2023Review
- SARS-CoV-2 cellular tropism and direct multiorgan failure in COVID-19 patients: Bioinformatic predictions, experimental observations, and open questions.Cell biology international · 2023Review
- Host microRNAs exhibit differential propensity to interact with SARS-CoV-2 and variants of concern.Biochimica et biophysica acta. Molecular basis of disease · 2023Article
- Machine Learning and COVID-19: Lessons from SARS-CoV-2.Advances in experimental medicine and biology · 2023Article
- Integrated Immunopeptidomic and Proteomic Analysis of COVID-19 lung biopsies.Frontiers in immunology · 2023Article
- SARS-CoV-2 infection of human-induced pluripotent stem cells-derived lung lineage cells evokes inflammatory and chemosensory responses by targeting mitochondrial pathways.Journal of cellular physiology · 2022Article
- Protease inhibitor Camostat Mesyalte blocks wild type SARS-CoV-2 and D614G viral entry in human engineered miniature lungs.Biomaterials · 2022Article
- GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation.Cells · 2022Article
- A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody.International journal of molecular sciences · 2022Review
- Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells.PLoS pathogens · 2022Article
- Immune-viral dynamics modeling for SARS-CoV-2 drug development.Clinical and translational science · 2021Article
- Co-Spray Dried Nafamostat Mesylate with Lecithin and Mannitol as Respirable Microparticles for Targeted Pulmonary Delivery: Pharmacokinetics and Lung Distribution in Rats.Pharmaceutics · 2021Article
- A model of the innate immune response to SARS-CoV-2 in the alveolar epithelium.Royal Society open science · 2021Article
- A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine.Medical hypotheses · 2021Article
- The total number and mass of SARS-CoV-2 virions.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
SARS-CoV-2 can infiltrate the lower respiratory tract, resulting in severe respiratory failure and a high death rate. Normally, the airway and alveolar epithelium can be rapidly reconstituted by multipotent stem cells after episodes of infection. Here, we analyzed published RNA-seq datasets and demonstrated that cells of four different lung epithelial stem cell types express SARS-CoV-2 entry factors, including Ace2. Thus, stem cells can be potentially infected by SARS-CoV-2, which may lead to defects in regeneration capacity partially accounting for the severity of SARS-CoV-2 infection and its consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.